These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2139337)

  • 1. The pharmacokinetics of doxazosin in patients with hypertension and renal impairment.
    Oliver RM; Upward JW; Dewhurst AG; Honeywell R; Renwick AG; Waller DG
    Br J Clin Pharmacol; 1990 Apr; 29(4):417-22. PubMed ID: 2139337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxazosin in patients with hypertension.
    Conrad KA; Fagan TC; Mackie MJ; Mayshar PV; Lee S; Souhrada JF; Falkner FC; Lazar JD
    Eur J Clin Pharmacol; 1988; 35(1):21-4. PubMed ID: 2975595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxazosin in renal impairment.
    Waller DG; Oliver RM
    J Hum Hypertens; 1990 Oct; 4 Suppl 3():47-9. PubMed ID: 2148195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose and steady-state pharmacokinetics of doxazosin given in combination with chlorothiazide to hypertensive subjects.
    Conway EL; McNeil JJ; Meng L; Drummer OH; Howes LG; Raymond K; Louis WJ
    Clin Pharmacokinet; 1989 Jun; 16(6):387-91. PubMed ID: 2525447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of doxazosin on blood pressure and renal haemodynamics of hypertensive patients with renal failure.
    Bailey RR; Nairn PL; Walker RJ
    N Z Med J; 1986 Dec; 99(815):942-5. PubMed ID: 2949169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind and cross-over comparison of once daily doxazosin and placebo with steady-state pharmacokinetics in elderly hypertensive patients.
    Scott PJ; Hosie J; Scott MG
    Eur J Clin Pharmacol; 1988; 34(2):119-23. PubMed ID: 2968267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacology of doxazosin in patients with essential hypertension.
    Cubeddu LX; Fuenmayor N; Caplan N; Ferry D
    Clin Pharmacol Ther; 1987 Apr; 41(4):439-49. PubMed ID: 2951051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension.
    Frick MH; Halttunen P; Himanen P; Huttunen M; Pörsti P; Pitkäjärvi T; Pöyhönen L; Pyykönen ML; Reinikainen P; Salmela P
    Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):55S-62S. PubMed ID: 2939868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxazosin in the treatment of patients with mild or moderate hypertension and mild or moderate renal insufficiency.
    Bartels AC; de Vries PM; Oe LP; van Bronswÿk H; Donker AJ; Réveillaud RJ; Fillastre JP; Zech P
    Am Heart J; 1988 Dec; 116(6 Pt 2):1772-7. PubMed ID: 2904749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concentration-effect relationships and individual responses to doxazosin in essential hypertension.
    Donnelly R; Elliott HL; Meredith PA; Reid JL
    Br J Clin Pharmacol; 1989 Nov; 28(5):517-26. PubMed ID: 2531605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antihypertensive effects of doxazosin: a clinical overview.
    Cox DA; Leader JP; Milson JA; Singleton W
    Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):83S-90S. PubMed ID: 2939872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise.
    Lund-Johansen P; Omvik P; Haugland H
    Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):45S-54S. PubMed ID: 2939867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension.
    Torvik D; Madsbu HP
    Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):69S-75S. PubMed ID: 2939870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter study of doxazosin in the treatment of severe essential hypertension.
    Soltero I; Guevara J; Silva H; Velasco M
    Am Heart J; 1988 Dec; 116(6 Pt 2):1767-71. PubMed ID: 2904748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin.
    Agabiti-Rosei E; Muiesan ML; Rizzoni D; Zulli R; Calebich S; Beschi M; Castellano M; Muiesan G
    J Hum Hypertens; 1992 Feb; 6(1):9-15. PubMed ID: 1349920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.
    Young RA; Brogden RN
    Drugs; 1988 May; 35(5):525-41. PubMed ID: 2899495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxazosin in the treatment of mild and moderate essential hypertension in general medical practice.
    van den Hogen AL
    Am Heart J; 1988 Dec; 116(6 Pt 2):1757-62. PubMed ID: 2904746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of doxazosin in systemic hypertension.
    Ames RP; Chrysant SG; Gonzalez F; Schnaper HW; Spann S; Velasquez MT
    Am J Cardiol; 1989 Jul; 64(3):203-8. PubMed ID: 2525870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-adrenoceptor blockade in patients with mild to moderate hypertension: long-term renal effects of doxazosin.
    Krusell LR; Christensen CK; Pedersen OL
    J Cardiovasc Pharmacol; 1992 Sep; 20(3):440-4. PubMed ID: 1279290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxazosin for treatment of hypertension.
    Med Lett Drugs Ther; 1991 Feb; 33(838):15-6. PubMed ID: 1825232
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.